Kymera (KYMR) Q3 2026 Earnings Call Transcript

Kymera reported Phase I results for KT-579 showing median IRF5 degradation above 90% in the five highest dose cohorts, up to 94%, and median inhibition of several inflammatory biomarkers of 87%-98%; the company reported no serious adverse events and plans a Phase Ib lupus study. KT-621’s 16-week Phase IIb atopic dermatitis study is complete, with data expected by year-end 2026, and management plans to start Phase III by mid-2027 if results and FDA discussions support it. Third-quarter net loss rose to $132.0 million from $82.2 million a year earlier, while R&D expense increased to $128.5 million from $74.1 million. The article’s takeaway reports $1.6 billion in cash and investments and runway into 2029, but the CFO’s transcript states approximately $1.6 million, an internal discrepancy in the source.

Analysis

The key valuation hinge is now the BROADEN 2 readout, not the encouraging KT-579 healthy-volunteer pharmacology. Deep target engagement and ex-vivo biomarker suppression establish mechanism, but do not demonstrate lupus benefit; the 14-day safety sample is also too small and short to settle chronic immunosuppression risk. For KT-621, an oral option could expand treatment rather than simply take share from injectable biologics: patients newly entering systemic care may later escalate to biologics, limiting the incumbent downside if the drug is effective but less potent. That market-expansion thesis remains company-research-based until clinical efficacy, persistence, and payer access are demonstrated; 98% OLE enrollment among eligible completers is not evidence of broad real-world retention.

KYMR has a near-term binary catalyst: year-end AD data, followed by FDA alignment and planned Phase III initiation by mid-2027. A weak placebo-adjusted clinical signal or tolerability issue could reset both the AD opportunity and confidence in STAT6 expansion to asthma; strong, consistent clinical endpoints could support a substantial pipeline re-rating. KT-579’s lupus study is a longer-dated, biomarker-led catalyst, with clinical measures explicitly exploratory. Rising R&D and the absence of expected collaboration revenue in the remainder of 2026 make execution and cash verification relevant as Phase III spending ramps. The source is internally inconsistent on cash: the takeaway says $1.6 billion, while the CFO transcript says $1.6 million. Confirm the 10-Q before relying on the stated runway. No quantified near-term earnings read-through is established for GILD or SNY from their partnered programs; NVS is a competitive reference, not a direct read-through.

Key Decisions for Investors

• Treat KYMR as an event-risk position into BROADEN 2, not as a de-risked pipeline compound. Avoid adding solely on KT-579 biomarker data; consider reducing or hedging existing exposure if unable to tolerate a sharp binary move.
• For investors seeking catalyst exposure, wait for BROADEN 2 and assess placebo-adjusted efficacy across key endpoints, itch/QOL, and safety together. Only consider adding after a coherent clinical profile; a favorable headline without consistent endpoints is insufficient. No price target is warranted from the supplied data.
• Watch the post-readout path to FDA alignment and Phase III initiation by mid-2027. Falsifiers include materially weak clinical separation from placebo, adverse tolerability findings, or a delayed/revised Phase III plan; any of these would undermine the market-expansion thesis.
• Verify cash and investments against the filed 10-Q before sizing a multi-quarter position: the article conflicts between $1.6 billion and $1.6 million. Also monitor cash burn as development costs rise; do not treat the stated 2029 runway as independently confirmed until reconciled.